434 related articles for article (PubMed ID: 25697595)
1. Hypomagnesemia and atherogenic dyslipidemia in chronic kidney disease: surrogate markers for increased cardiovascular risk.
Dey R; Rajappa M; Parameswaran S; Revathy G
Clin Exp Nephrol; 2015 Dec; 19(6):1054-61. PubMed ID: 25697595
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive lipid tetrad index, atherogenic index and lipid peroxidation: Surrogate markers for increased cardiovascular risk in psoriasis.
Sunitha S; Rajappa M; Thappa DM; Chandrashekar L; Munisamy M; Revathy G; Priyadarssini M
Indian J Dermatol Venereol Leprol; 2015; 81(5):464-71. PubMed ID: 26323680
[TBL] [Abstract][Full Text] [Related]
3. Thyroid dysfunction and dyslipidemia in chronic kidney disease patients.
Khatiwada S; Rajendra KC; Gautam S; Lamsal M; Baral N
BMC Endocr Disord; 2015 Oct; 15():65. PubMed ID: 26510920
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
[TBL] [Abstract][Full Text] [Related]
5. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
[TBL] [Abstract][Full Text] [Related]
6. Chronic Kidney Disease and Lipid Disorders.
Zubovic SV; Kristic S; Prevljak S; Pasic IS
Med Arch; 2016 Jun; 70(3):191-2. PubMed ID: 27594744
[TBL] [Abstract][Full Text] [Related]
7. Correlation of serum magnesium with dyslipidemia in patients on maintenance hemodialysis.
Ansari MR; Maheshwari N; Shaikh MA; Laghari MS; ; Lal K; Ahmed K
Saudi J Kidney Dis Transpl; 2012 Jan; 23(1):21-5. PubMed ID: 22237213
[TBL] [Abstract][Full Text] [Related]
8. Serum C-reactive protein levels in pre-dialysis chronic kidney disease patientsin southern Nigeria.
Adejumo OA; Okaka EI; Okwuonu CG; Iyawe IO; Odujoko OO
Ghana Med J; 2016 Mar; 50(1):31-8. PubMed ID: 27605722
[TBL] [Abstract][Full Text] [Related]
9. Serum Lipid Goal Attainment in Chronic Kidney Disease (CKD) Patients under the Japan Atherosclerosis Society (JAS) 2012 Guidelines.
Shimizu R; Torii H; Yasuda D; Hiraoka Y; Kitada N; Hashida T; Yoshimoto A; Kita T; Kume N
J Atheroscler Thromb; 2015; 22(9):949-57. PubMed ID: 25843151
[TBL] [Abstract][Full Text] [Related]
10. An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients.
Bermudez-Lopez M; Forne C; Amigo N; Bozic M; Arroyo D; Bretones T; Alonso N; Cambray S; Del Pino MD; Mauricio D; Gorriz JL; Fernandez E; Valdivielso JM
Expert Opin Ther Targets; 2019 Jul; 23(7):619-630. PubMed ID: 31100024
[No Abstract] [Full Text] [Related]
11. Serum magnesium, mortality, and cardiovascular disease in chronic kidney disease and end-stage renal disease patients: a systematic review and meta-analysis.
Xiong J; He T; Wang M; Nie L; Zhang Y; Wang Y; Huang Y; Feng B; Zhang J; Zhao J
J Nephrol; 2019 Oct; 32(5):791-802. PubMed ID: 30888644
[TBL] [Abstract][Full Text] [Related]
12. Surrogate markers for atherosclerosis in overweight subjects with atherogenic dyslipidemia: the GEMS project.
Genoud M; Wietlisbach V; Feihl F; Mermod A; Morin D; Darioli R; Nicod P; Mooser V; Waeber B; Hayoz D; Waeber G
Angiology; 2008; 59(4):484-92. PubMed ID: 18388087
[TBL] [Abstract][Full Text] [Related]
13. Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium magnesium citrate: a feasibility study.
Quiñones H; Hamdi T; Sakhaee K; Pasch A; Moe OW; Pak CYC
J Nephrol; 2019 Feb; 32(1):93-100. PubMed ID: 30465137
[TBL] [Abstract][Full Text] [Related]
14. High-Density Lipoprotein and Low-Density Lipoprotein Subfractions in Patients with Chronic Kidney Disease.
Rysz-Gorzynska M; Gluba-Brzozka A; Banach M
Curr Vasc Pharmacol; 2017; 15(2):144-151. PubMed ID: 27697068
[TBL] [Abstract][Full Text] [Related]
15. Association of cholesterol efflux capacity with plasmalogen levels of high-density lipoprotein: A cross-sectional study in chronic kidney disease patients.
Maeba R; Kojima KI; Nagura M; Komori A; Nishimukai M; Okazaki T; Uchida S
Atherosclerosis; 2018 Mar; 270():102-109. PubMed ID: 29407877
[TBL] [Abstract][Full Text] [Related]
16. Atherogenic dyslipidemia.
Hayden MR
J Cardiometab Syndr; 2006; 1(3):166-7. PubMed ID: 17679821
[No Abstract] [Full Text] [Related]
17. Lipid profile in pre-dialysis chronic kidney disease patients in southern Nigeria.
Adejumo OA; Okaka EI; Ojogwu LI
Ghana Med J; 2016 Mar; 50(1):44-9. PubMed ID: 27605724
[TBL] [Abstract][Full Text] [Related]
18. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
19. Body mass and atherogenic dyslipidemia as major determinants of blood levels of B-type natriuretic peptides in Arab subjects with acute coronary syndromes.
Akanji AO; Suresh CG; Al-Radwan R; Fatania HR
Metab Syndr Relat Disord; 2009 Dec; 7(6):563-9. PubMed ID: 19642911
[TBL] [Abstract][Full Text] [Related]
20. New perspectives on CKD-induced dyslipidemia.
Bermúdez-López M; Arroyo D; Betriu À; Masana L; Fernández E; Valdivielso JM
Expert Opin Ther Targets; 2017 Oct; 21(10):967-976. PubMed ID: 28829206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
